MAPT and Parkinson disease: How these biomarkers varied across different disease time points was evaluated by Mollenhauer et al. by sampling CSF α-syn, t-Tau, p-Tau, and Aβ42 levels at baseline and after 6 and 12 months in a large cohort of PD patients and matched HC.